{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:14:40Z","timestamp":1789442080744,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.clml.2025.04.006","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T19:09:12Z","timestamp":1744744152000},"page":"625-634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance"],"prefix":"10.1016","volume":"25","author":[{"given":"Sabarish","family":"Ayyappan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.clml.2025.04.006_bib0001","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.04.006_bib0002","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol Immunol"},{"issue":"4","key":"10.1016\/j.clml.2025.04.006_bib0003","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1615\/CritRevImmunol.v32.i4.10","article-title":"Regulatory roles of the tumor necrosis factor receptor BCMA","volume":"32","author":"Coquery","year":"2012","journal-title":"Crit Rev Immunol"},{"issue":"6","key":"10.1016\/j.clml.2025.04.006_bib0004","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.04.006_bib0005","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","article-title":"Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival","volume":"103","author":"Novak","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.04.006_bib0006","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.006_bib0007","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024"},{"issue":"10","key":"10.1016\/j.clml.2025.04.006_bib0008","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0009","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-208192","article-title":"MagnetisMM-3: long-term update and efficacy and safety of less frequent dosing of Elranatamab in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Prince","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.04.006_bib0010","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.006_bib0011","article-title":"Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: a pooled analysis from MagnetisMM studies","volume":"41","author":"Nooka","year":"2023"},{"issue":"22","key":"10.1016\/j.clml.2025.04.006_bib0012","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0013","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-179039","article-title":"Bivalent BCMA binding and low affinity CD3 T-cell engagement by Abbv-383 drives sustained activation with reduced T-cell exhaustion in preclinical models of Multiple myeloma","volume":"142","author":"Sharon","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-Human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0015","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1182\/blood-2022-167008","article-title":"A phase 1 first-in-Human study of Abbv-383, a BCMA \u00d7 CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Voorhees","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0016","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2024-206912","article-title":"A phase 1b study of step-up dosing with ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma","volume":"144","author":"Mian","year":"2024","journal-title":"Blood"},{"issue":"485","key":"10.1016\/j.clml.2025.04.006_bib0017","doi-asserted-by":"crossref","first-page":"eaau7746","DOI":"10.1126\/scitranslmed.aau7746","article-title":"GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells","volume":"11","author":"Smith","year":"2019","journal-title":"Sci Transl Med"},{"issue":"24","key":"10.1016\/j.clml.2025.04.006_bib0018","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0019","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.04.006_bib0020","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","article-title":"FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma","volume":"11","author":"Elkins","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.clml.2025.04.006_bib0021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1189\/jlb.0211096","article-title":"Fc receptor-like 5 promotes B cell proliferation and drives the development of cells displaying switched isotypes","volume":"91","author":"Dement-Brown","year":"2012","journal-title":"J Leukoc Biol"},{"issue":"7","key":"10.1016\/j.clml.2025.04.006_bib0022","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2017.165399","volume":"102","author":"Sobh","year":"2017","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0023","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0024","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration Cevostamab therapy in patients with relapsed\/refractory multiple myeloma: early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.04.006_bib0025","first-page":"260","article-title":"Preclinical characterization of ISB 1342, a CD38 \u00d7 CD3 T-cell engager for relapsed\/refractory multiple myeloma","volume":"142","author":"Pouleau","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.006_bib0026","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1002\/hem3.132","article-title":"Prophylactic tocilizumab reduces the incidence of cytokine release syndrome in relapsed\/refractory myeloma patients treated with teclistamab: implications for outpatient step-up dosing","volume":"8","author":"Korst","year":"2024","journal-title":"Hemasphere"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.006_bib0027","article-title":"Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1\/2 MajesTEC-1 study of teclistamab in relapsed\/refractory multiple myeloma (RRMM)","volume":"42","author":"van den Donk","year":"2024"},{"issue":"1","key":"10.1016\/j.clml.2025.04.006_bib0028","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2025.04.006_bib0029","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.006_bib0030","article-title":"Analysis of infections and parameters of humoral immunity in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) treated with talquetamab (tal) monotherapy in MonumenTAL-1","volume":"41","author":"Rodr\u00edguez-Otero","year":"2023"},{"issue":"1","key":"10.1016\/j.clml.2025.04.006_bib0031","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.04.006_bib0032","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.006_bib0033","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed\/refractory multiple myeloma (RRMM)","volume":"41","author":"Schinke","year":"2023"},{"issue":"2","key":"10.1016\/j.clml.2025.04.006_bib0034","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2406536","article-title":"Talquetamab plus Teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2025.04.006_bib0035","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMA\u00d7CD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by Daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.006_bib0036","article-title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated TRIMM-2 results","volume":"41","author":"Dholaria","year":"2023"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.04.006_bib0037","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/01.HS9.0000829556.56345.01","article-title":"Combination of subcutaneous teclistamab with daratumumab in patients with relapsed\/refractory multiple myeloma (RRMM): results from a phase 1b multicohort study","volume":"6","author":"Rodriguez-Otero","year":"2022","journal-title":"Hemasphere"},{"issue":"5","key":"10.1016\/j.clml.2025.04.006_bib0038","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1535-7163.MCT-22-0498","article-title":"IMiDs augment CD3-bispecific antibody-induced CD8+ T-cell cytotoxicity and expansion by enhancing IL2 production","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer Ther"},{"issue":"Suppl","key":"10.1016\/j.clml.2025.04.006_bib0039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/01.HS9.0000936248.01150.e8","article-title":"Single cohort results from Majestec-2: teclistamab (TEC) in combination with subcuteaneous daratumumab (DARA) and lenalidomide (LEN) in patients with multiple myeloma (MM)","volume":"7","author":"Searle","year":"2023","journal-title":"Hemasphere"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0040","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood-2024-200181","article-title":"Teclistamab, Daratumumab, and Pomalidomide in patients with relapsed\/refractory multiple myeloma: results from the Majestec-2 cohort a and Trimm-2 studies","volume":"144","author":"D\u2019Souza","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.04.006_bib0041","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1182\/blood-2022-157987","article-title":"Synergistic antitumor activity of Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+1 T cell engager (TCE), and Celmod agents in multiple myeloma (MM) preclinical models","volume":"140","author":"Paiva","year":"2022","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0042","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood-2023-187706","article-title":"Talquetamab + Pomalidomide in patients with relapsed\/refractory multiple myeloma: safety and preliminary efficacy results from the phase 1b MonumenTAL-2 study","volume":"142","author":"Matous","year":"2023","journal-title":"Blood"},{"issue":"4_Supplement","key":"10.1016\/j.clml.2025.04.006_bib0043","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS16-P6-14-01","article-title":"Abstract P6-14-01: enhanced efficacy of redirected T-cell therapy of TNBC with a trop-2\/CD3 bispecific antibody in combination with a checkpoint inhibitor","volume":"77","author":"Rossi","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.clml.2025.04.006_bib0044","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.clml.2025.04.006_bib0045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.2023022499","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.04.006_bib0046","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.clml.2025.04.006_bib0047","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for Multiple myeloma treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.clml.2025.04.006_bib0048","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0049","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of Talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.04.006_bib0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.clml.2025.04.006_bib0051","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jtct.2023.11.014","article-title":"PD1(+)TIGIT(+)2B4(+)KLRG1(+) cells might underlie T cell dysfunction in patients treated with BCMA-directed chimeric antigen receptor T cell therapy","volume":"30","author":"Mishra","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2025.04.006_bib0052","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1016\/j.clml.2025.04.006_bib0053","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.clml.2025.04.006_bib0054","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.clml.2025.04.006_bib0055","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.04.006_bib0056","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or Standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0057","doi-asserted-by":"crossref","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.clml.2025.04.006_bib0058","first-page":"7506","article-title":"Safety results from the phase 3 MajesTEC-7 study in patients (pts) with transplant ineligible\/not intended newly diagnosed multiple myeloma (NDMM)","volume":"42","author":"Touzeau","year":"2024"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0059","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2024-205608","volume":"144","author":"Zamagni","year":"2024","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2025.04.006_bib0060","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0061","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II platform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0062","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1182\/blood-2023-180013","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.04.006_bib0063","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2024-199542","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.04.006_bib64","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025001363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T03:15:21Z","timestamp":1755746121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025001363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":64,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2152265025001363"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}